Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyDihydrotestosterone
Identification
- Name
- Dihydrotestosterone
- Accession Number
- DB02901 (EXPT01199)
- Type
- Small Molecule
- Groups
- Illicit
- Description
A potent androgenic metabolite of testosterone. Dihydrotestosterone (DHT) is generated by a 5-alpha reduction of testosterone. Unlike testosterone, DHT cannot be aromatized to estradiol therefore DHT is considered a pure androgenic steroid. [PubChem]
- Structure
Structure for DB02901 (Dihydrotestosterone)
- Synonyms
- 17beta-Hydroxy-5alpha-androstan-3-one
- 17beta-Hydroxy-5alpha-androstane-3-one
- 17beta-Hydroxyandrostan-3-one
- 17β-hydroxy-3-oxo-5α-androstanone
- 17β-hydroxy-5α-androstan-3-one
- 4-Dihydrotestosterone
- 5alpha-Dihydrotestosterone
- 5α-DHT
- Androstanolone
- DHT
- Dihydrotestosteron
- Dihydrotestostérone
- Stanolone
- Product Ingredients
Ingredient UNII CAS InChI Key Stanolone acetate 63Z2Y83W8N 1164-91-6 ILCTUFVQFCIIDS-NGFSFWIMSA-N - International/Other Brands
- Anaboleen / Anabolex / Anaprotin / Andractim / Androlone / Cristerona MB / Neodrol / Proteina / Protona / Stanaprol
- Categories
- 5-Androstanon (3) Derivatives
- Androgens
- Androstanes
- Androstanols
- Genito Urinary System and Sex Hormones
- Gonadal Hormones
- Gonadal Steroid Hormones
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- P-glycoprotein/ABCB1 Substrates
- Sex Hormones and Modulators of the Genital System
- Steroids
- Testosterone Congeners
- UNII
- 08J2K08A3Y
- CAS number
- 521-18-6
- Weight
- Average: 290.4403
Monoisotopic: 290.224580204 - Chemical Formula
- C19H30O2
- InChI Key
- NVKAWKQGWWIWPM-ABEVXSGRSA-N
- InChI
- InChI=1S/C19H30O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h12,14-17,21H,3-11H2,1-2H3/t12-,14-,15-,16-,17-,18-,19-/m0/s1
- IUPAC Name
- (1S,2S,7S,10R,11S,14S,15S)-14-hydroxy-2,15-dimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadecan-5-one
- SMILES
- [H][[email protected]@]12CC[[email protected]](O)[[email protected]@]1(C)CC[[email protected]@]1([H])[[email protected]@]2([H])CC[[email protected]@]2([H])CC(=O)CC[[email protected]]12C
Pharmacology
- Indication
- Not Available
- Structured Indications
- Not Available
- Pharmacodynamics
- Not Available
- Mechanism of action
Target Actions Organism UAndrogen receptor Not Available Human UEstradiol 17-beta-dehydrogenase 1 Not Available Human UEstrogen receptor alpha Not Available Human UMineralocorticoid receptor Not Available Human - Absorption
Bioavailability is very low (0-2%) following oral administration.
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
Oral LD50 in rat is 7060 mg/kg. Oral LD50 in mouse is 3450 mg/kg.
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 16-Bromoepiandrosterone 16-Bromoepiandrosterone may increase the fluid retaining activities of Dihydrotestosterone. Investigational 19-norandrostenedione 19-norandrostenedione may increase the fluid retaining activities of Dihydrotestosterone. Experimental, Illicit 5-androstenedione 5-androstenedione may increase the fluid retaining activities of Dihydrotestosterone. Experimental, Illicit Acarbose Dihydrotestosterone may increase the hypoglycemic activities of Acarbose. Approved, Investigational Acenocoumarol Dihydrotestosterone may increase the anticoagulant activities of Acenocoumarol. Approved Acetaminophen The serum concentration of Dihydrotestosterone can be increased when it is combined with Acetaminophen. Approved Afatinib The serum concentration of Dihydrotestosterone can be increased when it is combined with Afatinib. Approved Albendazole The serum concentration of Dihydrotestosterone can be increased when it is combined with Albendazole. Approved, Vet Approved Albiglutide Dihydrotestosterone may increase the hypoglycemic activities of Albiglutide. Approved Alclometasone Alclometasone may increase the fluid retaining activities of Dihydrotestosterone. Approved Aldosterone The serum concentration of Dihydrotestosterone can be decreased when it is combined with Aldosterone. Experimental Alectinib The serum concentration of Dihydrotestosterone can be increased when it is combined with Alectinib. Approved Alfentanil The serum concentration of Dihydrotestosterone can be increased when it is combined with Alfentanil. Approved, Illicit Alogliptin Dihydrotestosterone may increase the hypoglycemic activities of Alogliptin. Approved Amantadine The serum concentration of Dihydrotestosterone can be increased when it is combined with Amantadine. Approved Amcinonide Amcinonide may increase the fluid retaining activities of Dihydrotestosterone. Approved Aminohippuric acid The serum concentration of Dihydrotestosterone can be increased when it is combined with Aminohippuric acid. Approved Amiodarone The serum concentration of Dihydrotestosterone can be decreased when it is combined with Amiodarone. Approved, Investigational Amitriptyline The serum concentration of Dihydrotestosterone can be increased when it is combined with Amitriptyline. Approved Amlodipine The serum concentration of Dihydrotestosterone can be increased when it is combined with Amlodipine. Approved Amprenavir The serum concentration of Dihydrotestosterone can be decreased when it is combined with Amprenavir. Approved Amsacrine The serum concentration of Dihydrotestosterone can be increased when it is combined with Amsacrine. Approved Androstenedione Androstenedione may increase the fluid retaining activities of Dihydrotestosterone. Experimental, Illicit Anecortave Anecortave may increase the fluid retaining activities of Dihydrotestosterone. Investigational anecortave acetate anecortave acetate may increase the fluid retaining activities of Dihydrotestosterone. Investigational Astemizole The serum concentration of Dihydrotestosterone can be increased when it is combined with Astemizole. Approved, Withdrawn Atamestane Atamestane may increase the fluid retaining activities of Dihydrotestosterone. Investigational Atazanavir The serum concentration of Dihydrotestosterone can be increased when it is combined with Atazanavir. Approved, Investigational Atenolol The serum concentration of Dihydrotestosterone can be increased when it is combined with Atenolol. Approved Atorvastatin The serum concentration of Dihydrotestosterone can be increased when it is combined with Atorvastatin. Approved Azelastine The serum concentration of Dihydrotestosterone can be increased when it is combined with Azelastine. Approved Azithromycin The serum concentration of Dihydrotestosterone can be increased when it is combined with Azithromycin. Approved Beclomethasone dipropionate Beclomethasone dipropionate may increase the fluid retaining activities of Dihydrotestosterone. Approved, Investigational Benzocaine The serum concentration of Dihydrotestosterone can be increased when it is combined with Benzocaine. Approved Bepridil The serum concentration of Dihydrotestosterone can be increased when it is combined with Bepridil. Approved, Withdrawn Betamethasone Betamethasone may increase the fluid retaining activities of Dihydrotestosterone. Approved, Vet Approved Biperiden The serum concentration of Dihydrotestosterone can be increased when it is combined with Biperiden. Approved Boceprevir The serum concentration of Dihydrotestosterone can be increased when it is combined with Boceprevir. Withdrawn Bosutinib The serum concentration of Dihydrotestosterone can be increased when it is combined with Bosutinib. Approved Bromocriptine The serum concentration of Dihydrotestosterone can be increased when it is combined with Bromocriptine. Approved, Investigational Budesonide Budesonide may increase the fluid retaining activities of Dihydrotestosterone. Approved Buprenorphine The serum concentration of Dihydrotestosterone can be increased when it is combined with Buprenorphine. Approved, Illicit, Investigational, Vet Approved Buspirone The serum concentration of Dihydrotestosterone can be increased when it is combined with Buspirone. Approved, Investigational Cabazitaxel The serum concentration of Dihydrotestosterone can be increased when it is combined with Cabazitaxel. Approved Caffeine The serum concentration of Dihydrotestosterone can be increased when it is combined with Caffeine. Approved Canagliflozin The serum concentration of Dihydrotestosterone can be increased when it is combined with Canagliflozin. Approved Candesartan The serum concentration of Dihydrotestosterone can be increased when it is combined with Candesartan. Approved Captopril The serum concentration of Dihydrotestosterone can be increased when it is combined with Captopril. Approved Carbamazepine The serum concentration of Dihydrotestosterone can be decreased when it is combined with Carbamazepine. Approved, Investigational Carvedilol The serum concentration of Dihydrotestosterone can be increased when it is combined with Carvedilol. Approved, Investigational Caspofungin The serum concentration of Dihydrotestosterone can be increased when it is combined with Caspofungin. Approved Chloroquine The serum concentration of Dihydrotestosterone can be increased when it is combined with Chloroquine. Approved, Vet Approved Chlorpromazine The serum concentration of Dihydrotestosterone can be increased when it is combined with Chlorpromazine. Approved, Vet Approved Chlorpropamide The serum concentration of Dihydrotestosterone can be increased when it is combined with Chlorpropamide. Approved Chlorprothixene The serum concentration of Dihydrotestosterone can be increased when it is combined with Chlorprothixene. Approved, Withdrawn Cholesterol The serum concentration of Dihydrotestosterone can be increased when it is combined with Cholesterol. Experimental Cholic Acid The serum concentration of Dihydrotestosterone can be decreased when it is combined with Cholic Acid. Approved Ciclesonide Ciclesonide may increase the fluid retaining activities of Dihydrotestosterone. Approved, Investigational Cilazapril The serum concentration of Dihydrotestosterone can be increased when it is combined with Cilazapril. Approved Cimetidine The serum concentration of Dihydrotestosterone can be decreased when it is combined with Cimetidine. Approved Ciprofloxacin The serum concentration of Dihydrotestosterone can be increased when it is combined with Ciprofloxacin. Approved, Investigational Citalopram The serum concentration of Dihydrotestosterone can be increased when it is combined with Citalopram. Approved Clarithromycin The serum concentration of Dihydrotestosterone can be increased when it is combined with Clarithromycin. Approved Clobetasol Clobetasol may increase the fluid retaining activities of Dihydrotestosterone. Investigational Clobetasol propionate Clobetasol propionate may increase the fluid retaining activities of Dihydrotestosterone. Approved Clobetasone Clobetasone may increase the fluid retaining activities of Dihydrotestosterone. Approved Clocortolone Clocortolone may increase the fluid retaining activities of Dihydrotestosterone. Approved Clofazimine The serum concentration of Dihydrotestosterone can be increased when it is combined with Clofazimine. Approved, Investigational Clomipramine The serum concentration of Dihydrotestosterone can be increased when it is combined with Clomipramine. Approved, Vet Approved Clorindione Dihydrotestosterone may increase the anticoagulant activities of Clorindione. Experimental Clotrimazole The serum concentration of Dihydrotestosterone can be decreased when it is combined with Clotrimazole. Approved, Vet Approved Cobicistat The serum concentration of Dihydrotestosterone can be increased when it is combined with Cobicistat. Approved Colchicine The serum concentration of Dihydrotestosterone can be increased when it is combined with Colchicine. Approved Colforsin The serum concentration of Dihydrotestosterone can be increased when it is combined with Colforsin. Experimental Conestat alfa Dihydrotestosterone may increase the thrombogenic activities of Conestat alfa. Approved Cortexolone 17α-propionate Cortexolone 17α-propionate may increase the fluid retaining activities of Dihydrotestosterone. Investigational Corticosterone Corticosterone may increase the fluid retaining activities of Dihydrotestosterone. Experimental Cortisone acetate Cortisone acetate may increase the fluid retaining activities of Dihydrotestosterone. Approved Crizotinib The serum concentration of Dihydrotestosterone can be increased when it is combined with Crizotinib. Approved Cyclophosphamide The serum concentration of Dihydrotestosterone can be increased when it is combined with Cyclophosphamide. Approved, Investigational Cyclosporine Dihydrotestosterone may increase the hepatotoxic activities of Cyclosporine. Approved, Investigational, Vet Approved Daclatasvir The serum concentration of Dihydrotestosterone can be increased when it is combined with Daclatasvir. Approved Dactinomycin The serum concentration of Dihydrotestosterone can be increased when it is combined with Dactinomycin. Approved Dapagliflozin Dihydrotestosterone may increase the hypoglycemic activities of Dapagliflozin. Approved Dasatinib The serum concentration of Dihydrotestosterone can be increased when it is combined with Dasatinib. Approved, Investigational Daunorubicin The serum concentration of Dihydrotestosterone can be decreased when it is combined with Daunorubicin. Approved Desipramine The serum concentration of Dihydrotestosterone can be increased when it is combined with Desipramine. Approved Desloratadine The serum concentration of Dihydrotestosterone can be increased when it is combined with Desloratadine. Approved, Investigational Desoximetasone Desoximetasone may increase the fluid retaining activities of Dihydrotestosterone. Approved Desoxycorticosterone acetate Desoxycorticosterone acetate may increase the fluid retaining activities of Dihydrotestosterone. Approved Desoxycorticosterone Pivalate Desoxycorticosterone Pivalate may increase the fluid retaining activities of Dihydrotestosterone. Experimental, Vet Approved Dexamethasone The serum concentration of Dihydrotestosterone can be decreased when it is combined with Dexamethasone. Approved, Investigational, Vet Approved Dexamethasone isonicotinate Dexamethasone isonicotinate may increase the fluid retaining activities of Dihydrotestosterone. Vet Approved Dextromethorphan The serum concentration of Dihydrotestosterone can be increased when it is combined with Dextromethorphan. Approved Diclofenac The serum concentration of Dihydrotestosterone can be increased when it is combined with Diclofenac. Approved, Vet Approved Dicoumarol Dihydrotestosterone may increase the anticoagulant activities of Dicoumarol. Approved Diflorasone Diflorasone may increase the fluid retaining activities of Dihydrotestosterone. Approved Difluocortolone Difluocortolone may increase the fluid retaining activities of Dihydrotestosterone. Approved Difluprednate Difluprednate may increase the fluid retaining activities of Dihydrotestosterone. Approved Digoxin The serum concentration of Dihydrotestosterone can be decreased when it is combined with Digoxin. Approved Dihydroergotamine The serum concentration of Dihydrotestosterone can be increased when it is combined with Dihydroergotamine. Approved Diltiazem The serum concentration of Dihydrotestosterone can be increased when it is combined with Diltiazem. Approved Diphenadione Dihydrotestosterone may increase the anticoagulant activities of Diphenadione. Experimental Dipyridamole The serum concentration of Dihydrotestosterone can be increased when it is combined with Dipyridamole. Approved Disopyramide Dihydrotestosterone may increase the hypoglycemic activities of Disopyramide. Approved Doxazosin The serum concentration of Dihydrotestosterone can be increased when it is combined with Doxazosin. Approved Doxepin The serum concentration of Dihydrotestosterone can be increased when it is combined with Doxepin. Approved Doxorubicin The serum concentration of Dihydrotestosterone can be decreased when it is combined with Doxorubicin. Approved, Investigational Dronabinol The serum concentration of Dihydrotestosterone can be increased when it is combined with Dronabinol. Approved, Illicit Dronedarone The serum concentration of Dihydrotestosterone can be increased when it is combined with Dronedarone. Approved Dulaglutide Dihydrotestosterone may increase the hypoglycemic activities of Dulaglutide. Approved Elbasvir The serum concentration of Dihydrotestosterone can be increased when it is combined with Elbasvir. Approved Empagliflozin Dihydrotestosterone may increase the hypoglycemic activities of Empagliflozin. Approved Enalapril The serum concentration of Dihydrotestosterone can be increased when it is combined with Enalapril. Approved, Vet Approved Enasidenib The serum concentration of Dihydrotestosterone can be increased when it is combined with Enasidenib. Approved Enzalutamide The serum concentration of Dihydrotestosterone can be increased when it is combined with Enzalutamide. Approved Equilenin Equilenin may increase the fluid retaining activities of Dihydrotestosterone. Experimental Equilin Equilin may increase the fluid retaining activities of Dihydrotestosterone. Approved Ergonovine The serum concentration of Dihydrotestosterone can be increased when it is combined with Ergonovine. Approved Ergotamine The serum concentration of Dihydrotestosterone can be increased when it is combined with Ergotamine. Approved Erythromycin The serum concentration of Dihydrotestosterone can be decreased when it is combined with Erythromycin. Approved, Vet Approved Estramustine The serum concentration of Dihydrotestosterone can be increased when it is combined with Estramustine. Approved Estriol The serum concentration of Dihydrotestosterone can be decreased when it is combined with Estriol. Approved, Vet Approved Estrone The serum concentration of Dihydrotestosterone can be decreased when it is combined with Estrone. Approved Estrone sulfate Estrone sulfate may increase the fluid retaining activities of Dihydrotestosterone. Approved Ethyl biscoumacetate Dihydrotestosterone may increase the anticoagulant activities of Ethyl biscoumacetate. Withdrawn Etoposide The serum concentration of Dihydrotestosterone can be increased when it is combined with Etoposide. Approved Etravirine The serum concentration of Dihydrotestosterone can be increased when it is combined with Etravirine. Approved Exenatide Dihydrotestosterone may increase the hypoglycemic activities of Exenatide. Approved, Investigational Felodipine The serum concentration of Dihydrotestosterone can be increased when it is combined with Felodipine. Approved, Investigational Fentanyl The serum concentration of Dihydrotestosterone can be increased when it is combined with Fentanyl. Approved, Illicit, Investigational, Vet Approved Fexofenadine The serum concentration of Dihydrotestosterone can be increased when it is combined with Fexofenadine. Approved Fidaxomicin The serum concentration of Dihydrotestosterone can be increased when it is combined with Fidaxomicin. Approved fluasterone fluasterone may increase the fluid retaining activities of Dihydrotestosterone. Investigational Fluconazole The serum concentration of Dihydrotestosterone can be increased when it is combined with Fluconazole. Approved Fludrocortisone Fludrocortisone may increase the fluid retaining activities of Dihydrotestosterone. Approved Fluindione Dihydrotestosterone may increase the anticoagulant activities of Fluindione. Investigational Flumethasone Flumethasone may increase the fluid retaining activities of Dihydrotestosterone. Approved, Vet Approved Fluocinolone Acetonide Fluocinolone Acetonide may increase the fluid retaining activities of Dihydrotestosterone. Approved, Investigational, Vet Approved Fluocinonide Fluocinonide may increase the fluid retaining activities of Dihydrotestosterone. Approved, Investigational Fluocortolone Fluocortolone may increase the fluid retaining activities of Dihydrotestosterone. Approved, Withdrawn Fluorometholone Fluorometholone may increase the fluid retaining activities of Dihydrotestosterone. Approved Fluoxetine The serum concentration of Dihydrotestosterone can be increased when it is combined with Fluoxetine. Approved, Vet Approved Flupentixol The serum concentration of Dihydrotestosterone can be increased when it is combined with Flupentixol. Approved, Withdrawn Fluphenazine The serum concentration of Dihydrotestosterone can be increased when it is combined with Fluphenazine. Approved Fluprednidene Fluprednidene may increase the fluid retaining activities of Dihydrotestosterone. Approved, Withdrawn Fluprednisolone Fluprednisolone may increase the fluid retaining activities of Dihydrotestosterone. Approved Flurandrenolide Flurandrenolide may increase the fluid retaining activities of Dihydrotestosterone. Approved Flurazepam The serum concentration of Dihydrotestosterone can be increased when it is combined with Flurazepam. Approved, Illicit Fluvoxamine The serum concentration of Dihydrotestosterone can be increased when it is combined with Fluvoxamine. Approved, Investigational Formestane Formestane may increase the fluid retaining activities of Dihydrotestosterone. Approved, Investigational, Withdrawn Gefitinib The serum concentration of Dihydrotestosterone can be increased when it is combined with Gefitinib. Approved, Investigational Genistein The serum concentration of Dihydrotestosterone can be increased when it is combined with Genistein. Investigational Glecaprevir The serum concentration of Dihydrotestosterone can be increased when it is combined with Glecaprevir. Approved Gliclazide Dihydrotestosterone may increase the hypoglycemic activities of Gliclazide. Approved Glimepiride Dihydrotestosterone may increase the hypoglycemic activities of Glimepiride. Approved Glipizide Dihydrotestosterone may increase the hypoglycemic activities of Glipizide. Approved Glyburide The serum concentration of Dihydrotestosterone can be increased when it is combined with Glyburide. Approved Glycerin The serum concentration of Dihydrotestosterone can be increased when it is combined with Glycerin. Approved, Investigational Gramicidin D The serum concentration of Dihydrotestosterone can be increased when it is combined with Gramicidin D. Approved Grepafloxacin The serum concentration of Dihydrotestosterone can be increased when it is combined with Grepafloxacin. Withdrawn Haloperidol The serum concentration of Dihydrotestosterone can be increased when it is combined with Haloperidol. Approved HE3286 HE3286 may increase the fluid retaining activities of Dihydrotestosterone. Investigational Human C1-esterase inhibitor Dihydrotestosterone may increase the thrombogenic activities of Human C1-esterase inhibitor. Approved Hydrocortisone The serum concentration of Dihydrotestosterone can be increased when it is combined with Hydrocortisone. Approved, Vet Approved Idelalisib The serum concentration of Dihydrotestosterone can be increased when it is combined with Idelalisib. Approved Imatinib The serum concentration of Dihydrotestosterone can be increased when it is combined with Imatinib. Approved Imipramine The serum concentration of Dihydrotestosterone can be increased when it is combined with Imipramine. Approved Indinavir The serum concentration of Dihydrotestosterone can be decreased when it is combined with Indinavir. Approved Indomethacin The serum concentration of Dihydrotestosterone can be increased when it is combined with Indomethacin. Approved, Investigational Insulin Aspart Dihydrotestosterone may increase the hypoglycemic activities of Insulin Aspart. Approved Insulin Detemir Dihydrotestosterone may increase the hypoglycemic activities of Insulin Detemir. Approved Insulin Glargine Dihydrotestosterone may increase the hypoglycemic activities of Insulin Glargine. Approved Insulin Glulisine Dihydrotestosterone may increase the hypoglycemic activities of Insulin Glulisine. Approved Insulin Human Dihydrotestosterone may increase the hypoglycemic activities of Insulin Human. Approved, Investigational Insulin Lispro Dihydrotestosterone may increase the hypoglycemic activities of Insulin Lispro. Approved Isavuconazonium The serum concentration of Dihydrotestosterone can be increased when it is combined with Isavuconazonium. Approved, Investigational Istaroxime Istaroxime may increase the fluid retaining activities of Dihydrotestosterone. Investigational Itraconazole The serum concentration of Dihydrotestosterone can be increased when it is combined with Itraconazole. Approved, Investigational Ivacaftor The serum concentration of Dihydrotestosterone can be increased when it is combined with Ivacaftor. Approved Ivermectin The serum concentration of Dihydrotestosterone can be increased when it is combined with Ivermectin. Approved, Vet Approved Ketamine The serum concentration of Dihydrotestosterone can be increased when it is combined with Ketamine. Approved, Vet Approved Ketoconazole The serum concentration of Dihydrotestosterone can be increased when it is combined with Ketoconazole. Approved, Investigational Lansoprazole The serum concentration of Dihydrotestosterone can be increased when it is combined with Lansoprazole. Approved, Investigational Lapatinib The serum concentration of Dihydrotestosterone can be increased when it is combined with Lapatinib. Approved, Investigational Levofloxacin The serum concentration of Dihydrotestosterone can be increased when it is combined with Levofloxacin. Approved, Investigational Levothyroxine The serum concentration of Dihydrotestosterone can be decreased when it is combined with Levothyroxine. Approved Lidocaine The serum concentration of Dihydrotestosterone can be increased when it is combined with Lidocaine. Approved, Vet Approved Liothyronine The serum concentration of Dihydrotestosterone can be decreased when it is combined with Liothyronine. Approved, Vet Approved Liotrix The serum concentration of Dihydrotestosterone can be decreased when it is combined with Liotrix. Approved Liraglutide Dihydrotestosterone may increase the hypoglycemic activities of Liraglutide. Approved Lisinopril The serum concentration of Dihydrotestosterone can be increased when it is combined with Lisinopril. Approved, Investigational Lomitapide The serum concentration of Dihydrotestosterone can be increased when it is combined with Lomitapide. Approved Loperamide The serum concentration of Dihydrotestosterone can be increased when it is combined with Loperamide. Approved Lopinavir The serum concentration of Dihydrotestosterone can be increased when it is combined with Lopinavir. Approved Loratadine The serum concentration of Dihydrotestosterone can be increased when it is combined with Loratadine. Approved Losartan The serum concentration of Dihydrotestosterone can be increased when it is combined with Losartan. Approved Lovastatin The serum concentration of Dihydrotestosterone can be increased when it is combined with Lovastatin. Approved, Investigational Lumacaftor The serum concentration of Dihydrotestosterone can be decreased when it is combined with Lumacaftor. Approved Maprotiline The serum concentration of Dihydrotestosterone can be increased when it is combined with Maprotiline. Approved ME-609 ME-609 may increase the fluid retaining activities of Dihydrotestosterone. Investigational Mebendazole The serum concentration of Dihydrotestosterone can be increased when it is combined with Mebendazole. Approved, Vet Approved Mecasermin Dihydrotestosterone may increase the hypoglycemic activities of Mecasermin. Approved, Investigational Medrysone Medrysone may increase the fluid retaining activities of Dihydrotestosterone. Approved Mefloquine The serum concentration of Dihydrotestosterone can be increased when it is combined with Mefloquine. Approved Megestrol acetate The serum concentration of Dihydrotestosterone can be increased when it is combined with Megestrol acetate. Approved, Vet Approved Melengestrol Melengestrol may increase the fluid retaining activities of Dihydrotestosterone. Vet Approved Meprobamate The serum concentration of Dihydrotestosterone can be increased when it is combined with Meprobamate. Approved, Illicit Metformin Dihydrotestosterone may increase the hypoglycemic activities of Metformin. Approved Methadone The serum concentration of Dihydrotestosterone can be increased when it is combined with Methadone. Approved Methylprednisolone Methylprednisolone may increase the fluid retaining activities of Dihydrotestosterone. Approved, Vet Approved Metoprolol The serum concentration of Dihydrotestosterone can be increased when it is combined with Metoprolol. Approved, Investigational Mibefradil The serum concentration of Dihydrotestosterone can be increased when it is combined with Mibefradil. Withdrawn Miconazole The serum concentration of Dihydrotestosterone can be increased when it is combined with Miconazole. Approved, Investigational, Vet Approved Midazolam The serum concentration of Dihydrotestosterone can be decreased when it is combined with Midazolam. Approved, Illicit Mifepristone The serum concentration of Dihydrotestosterone can be decreased when it is combined with Mifepristone. Approved, Investigational Miglitol Dihydrotestosterone may increase the hypoglycemic activities of Miglitol. Approved Mitomycin The serum concentration of Dihydrotestosterone can be increased when it is combined with Mitomycin. Approved Mitoxantrone The serum concentration of Dihydrotestosterone can be decreased when it is combined with Mitoxantrone. Approved, Investigational Morphine The serum concentration of Dihydrotestosterone can be increased when it is combined with Morphine. Approved, Investigational Naltrexone The serum concentration of Dihydrotestosterone can be increased when it is combined with Naltrexone. Approved, Investigational, Vet Approved Naringenin The serum concentration of Dihydrotestosterone can be increased when it is combined with Naringenin. Experimental Nateglinide Dihydrotestosterone may increase the hypoglycemic activities of Nateglinide. Approved, Investigational NCX 1022 NCX 1022 may increase the fluid retaining activities of Dihydrotestosterone. Investigational Nefazodone The serum concentration of Dihydrotestosterone can be decreased when it is combined with Nefazodone. Approved, Withdrawn Nelfinavir The serum concentration of Dihydrotestosterone can be decreased when it is combined with Nelfinavir. Approved Neostigmine The serum concentration of Dihydrotestosterone can be increased when it is combined with Neostigmine. Approved, Vet Approved Nicardipine The serum concentration of Dihydrotestosterone can be increased when it is combined with Nicardipine. Approved Nifedipine The serum concentration of Dihydrotestosterone can be decreased when it is combined with Nifedipine. Approved Nilotinib The serum concentration of Dihydrotestosterone can be increased when it is combined with Nilotinib. Approved, Investigational Nisoldipine The serum concentration of Dihydrotestosterone can be increased when it is combined with Nisoldipine. Approved Nitrazepam The serum concentration of Dihydrotestosterone can be increased when it is combined with Nitrazepam. Approved Nitrendipine The serum concentration of Dihydrotestosterone can be increased when it is combined with Nitrendipine. Approved Norethisterone The serum concentration of Dihydrotestosterone can be decreased when it is combined with Norethisterone. Approved Oleoyl-estrone Oleoyl-estrone may increase the fluid retaining activities of Dihydrotestosterone. Investigational Omeprazole The serum concentration of Dihydrotestosterone can be increased when it is combined with Omeprazole. Approved, Investigational, Vet Approved P-Nitrophenol The serum concentration of Dihydrotestosterone can be increased when it is combined with P-Nitrophenol. Experimental Paclitaxel The serum concentration of Dihydrotestosterone can be increased when it is combined with Paclitaxel. Approved, Vet Approved Palmitic Acid The serum concentration of Dihydrotestosterone can be increased when it is combined with Palmitic Acid. Experimental Pantoprazole The serum concentration of Dihydrotestosterone can be increased when it is combined with Pantoprazole. Approved Paramethasone Paramethasone may increase the fluid retaining activities of Dihydrotestosterone. Approved Paroxetine The serum concentration of Dihydrotestosterone can be increased when it is combined with Paroxetine. Approved, Investigational Pentamidine Dihydrotestosterone may increase the hypoglycemic activities of Pentamidine. Approved Perindopril The serum concentration of Dihydrotestosterone can be increased when it is combined with Perindopril. Approved Phenindione Dihydrotestosterone may increase the anticoagulant activities of Phenindione. Approved Phenobarbital The serum concentration of Dihydrotestosterone can be decreased when it is combined with Phenobarbital. Approved Phenprocoumon Dihydrotestosterone may increase the anticoagulant activities of Phenprocoumon. Approved Pibrentasvir The serum concentration of Dihydrotestosterone can be increased when it is combined with Pibrentasvir. Approved Pimozide The serum concentration of Dihydrotestosterone can be increased when it is combined with Pimozide. Approved Pioglitazone Dihydrotestosterone may increase the hypoglycemic activities of Pioglitazone. Approved, Investigational Platelet Activating Factor The serum concentration of Dihydrotestosterone can be decreased when it is combined with Platelet Activating Factor. Experimental Ponatinib The serum concentration of Dihydrotestosterone can be increased when it is combined with Ponatinib. Approved Posaconazole The serum concentration of Dihydrotestosterone can be increased when it is combined with Posaconazole. Approved, Investigational, Vet Approved Pramlintide Dihydrotestosterone may increase the hypoglycemic activities of Pramlintide. Approved, Investigational Prasterone Prasterone may increase the fluid retaining activities of Dihydrotestosterone. Approved, Nutraceutical Prasterone sulfate Prasterone sulfate may increase the fluid retaining activities of Dihydrotestosterone. Investigational Pravastatin The serum concentration of Dihydrotestosterone can be increased when it is combined with Pravastatin. Approved Prazosin The serum concentration of Dihydrotestosterone can be increased when it is combined with Prazosin. Approved Prednicarbate Prednicarbate may increase the fluid retaining activities of Dihydrotestosterone. Approved Prednisolone Prednisolone may increase the fluid retaining activities of Dihydrotestosterone. Approved, Vet Approved Prednisone The serum concentration of Dihydrotestosterone can be increased when it is combined with Prednisone. Approved, Vet Approved Pregnenolone Pregnenolone may increase the fluid retaining activities of Dihydrotestosterone. Experimental Probenecid The serum concentration of Dihydrotestosterone can be increased when it is combined with Probenecid. Approved Progesterone The serum concentration of Dihydrotestosterone can be decreased when it is combined with Progesterone. Approved, Vet Approved Promethazine The serum concentration of Dihydrotestosterone can be increased when it is combined with Promethazine. Approved Propafenone The serum concentration of Dihydrotestosterone can be increased when it is combined with Propafenone. Approved Propranolol The serum concentration of Dihydrotestosterone can be increased when it is combined with Propranolol. Approved, Investigational Protriptyline The serum concentration of Dihydrotestosterone can be increased when it is combined with Protriptyline. Approved Quercetin The serum concentration of Dihydrotestosterone can be increased when it is combined with Quercetin. Experimental Quinacrine The serum concentration of Dihydrotestosterone can be increased when it is combined with Quinacrine. Approved Quinidine The serum concentration of Dihydrotestosterone can be increased when it is combined with Quinidine. Approved Quinine The serum concentration of Dihydrotestosterone can be increased when it is combined with Quinine. Approved Ranitidine The serum concentration of Dihydrotestosterone can be increased when it is combined with Ranitidine. Approved Ranolazine The serum concentration of Dihydrotestosterone can be increased when it is combined with Ranolazine. Approved, Investigational Reboxetine The serum concentration of Dihydrotestosterone can be increased when it is combined with Reboxetine. Approved, Investigational Regorafenib The serum concentration of Dihydrotestosterone can be increased when it is combined with Regorafenib. Approved Repaglinide Dihydrotestosterone may increase the hypoglycemic activities of Repaglinide. Approved, Investigational Reserpine The serum concentration of Dihydrotestosterone can be decreased when it is combined with Reserpine. Approved Rifampicin The serum concentration of Dihydrotestosterone can be decreased when it is combined with Rifampicin. Approved Rilpivirine The serum concentration of Dihydrotestosterone can be increased when it is combined with Rilpivirine. Approved Rimexolone Rimexolone may increase the fluid retaining activities of Dihydrotestosterone. Approved Ritonavir The serum concentration of Dihydrotestosterone can be decreased when it is combined with Ritonavir. Approved, Investigational Rolapitant The serum concentration of Dihydrotestosterone can be increased when it is combined with Rolapitant. Approved Rosiglitazone Dihydrotestosterone may increase the hypoglycemic activities of Rosiglitazone. Approved, Investigational Saquinavir The serum concentration of Dihydrotestosterone can be decreased when it is combined with Saquinavir. Approved, Investigational Saxagliptin Dihydrotestosterone may increase the hypoglycemic activities of Saxagliptin. Approved Scopolamine The serum concentration of Dihydrotestosterone can be increased when it is combined with Scopolamine. Approved Selegiline The serum concentration of Dihydrotestosterone can be increased when it is combined with Selegiline. Approved, Investigational, Vet Approved Sertraline The serum concentration of Dihydrotestosterone can be increased when it is combined with Sertraline. Approved Simeprevir The serum concentration of Dihydrotestosterone can be increased when it is combined with Simeprevir. Approved Simvastatin The serum concentration of Dihydrotestosterone can be increased when it is combined with Simvastatin. Approved Sirolimus The serum concentration of Dihydrotestosterone can be decreased when it is combined with Sirolimus. Approved, Investigational Sitagliptin Dihydrotestosterone may increase the hypoglycemic activities of Sitagliptin. Approved, Investigational Sorafenib The serum concentration of Dihydrotestosterone can be increased when it is combined with Sorafenib. Approved, Investigational Spironolactone The serum concentration of Dihydrotestosterone can be increased when it is combined with Spironolactone. Approved St. John's Wort The serum concentration of Dihydrotestosterone can be decreased when it is combined with St. John's Wort. Nutraceutical Staurosporine The serum concentration of Dihydrotestosterone can be increased when it is combined with Staurosporine. Experimental Streptozocin The serum concentration of Dihydrotestosterone can be decreased when it is combined with Streptozocin. Approved Sulfadiazine Dihydrotestosterone may increase the hypoglycemic activities of Sulfadiazine. Approved, Vet Approved Sulfamethoxazole Dihydrotestosterone may increase the hypoglycemic activities of Sulfamethoxazole. Approved Sulfinpyrazone The serum concentration of Dihydrotestosterone can be increased when it is combined with Sulfinpyrazone. Approved Sulfisoxazole Dihydrotestosterone may increase the hypoglycemic activities of Sulfisoxazole. Approved, Vet Approved Sumatriptan The serum concentration of Dihydrotestosterone can be increased when it is combined with Sumatriptan. Approved, Investigational Sunitinib The serum concentration of Dihydrotestosterone can be increased when it is combined with Sunitinib. Approved, Investigational Tacrine The serum concentration of Dihydrotestosterone can be increased when it is combined with Tacrine. Withdrawn Tacrolimus The serum concentration of Dihydrotestosterone can be decreased when it is combined with Tacrolimus. Approved, Investigational Tamoxifen The serum concentration of Dihydrotestosterone can be decreased when it is combined with Tamoxifen. Approved Taurocholic Acid The serum concentration of Dihydrotestosterone can be increased when it is combined with Taurocholic Acid. Experimental Telaprevir The serum concentration of Dihydrotestosterone can be increased when it is combined with Telaprevir. Withdrawn Telmisartan The serum concentration of Dihydrotestosterone can be increased when it is combined with Telmisartan. Approved, Investigational Temsirolimus The serum concentration of Dihydrotestosterone can be increased when it is combined with Temsirolimus. Approved Terazosin The serum concentration of Dihydrotestosterone can be increased when it is combined with Terazosin. Approved Terfenadine The serum concentration of Dihydrotestosterone can be increased when it is combined with Terfenadine. Withdrawn Tesmilifene The serum concentration of Dihydrotestosterone can be decreased when it is combined with Tesmilifene. Investigational Testosterone The serum concentration of Dihydrotestosterone can be increased when it is combined with Testosterone. Approved, Investigational Ticagrelor The serum concentration of Dihydrotestosterone can be increased when it is combined with Ticagrelor. Approved Tioclomarol Dihydrotestosterone may increase the anticoagulant activities of Tioclomarol. Experimental Tixocortol Tixocortol may increase the fluid retaining activities of Dihydrotestosterone. Approved Tolazamide Dihydrotestosterone may increase the hypoglycemic activities of Tolazamide. Approved Tolbutamide Dihydrotestosterone may increase the hypoglycemic activities of Tolbutamide. Approved Tolvaptan The serum concentration of Dihydrotestosterone can be increased when it is combined with Tolvaptan. Approved Trazodone The serum concentration of Dihydrotestosterone can be decreased when it is combined with Trazodone. Approved, Investigational Triamcinolone Triamcinolone may increase the fluid retaining activities of Dihydrotestosterone. Approved, Vet Approved Trifluoperazine The serum concentration of Dihydrotestosterone can be increased when it is combined with Trifluoperazine. Approved Triflupromazine The serum concentration of Dihydrotestosterone can be increased when it is combined with Triflupromazine. Approved, Vet Approved Trimethoprim The serum concentration of Dihydrotestosterone can be decreased when it is combined with Trimethoprim. Approved, Vet Approved Trimipramine The serum concentration of Dihydrotestosterone can be increased when it is combined with Trimipramine. Approved Troleandomycin The serum concentration of Dihydrotestosterone can be increased when it is combined with Troleandomycin. Approved Velpatasvir The serum concentration of Dihydrotestosterone can be increased when it is combined with Velpatasvir. Approved Venlafaxine The serum concentration of Dihydrotestosterone can be increased when it is combined with Venlafaxine. Approved Verapamil The serum concentration of Dihydrotestosterone can be decreased when it is combined with Verapamil. Approved Vinblastine The serum concentration of Dihydrotestosterone can be decreased when it is combined with Vinblastine. Approved Vincristine The serum concentration of Dihydrotestosterone can be decreased when it is combined with Vincristine. Approved, Investigational Vinorelbine The serum concentration of Dihydrotestosterone can be increased when it is combined with Vinorelbine. Approved, Investigational Voxilaprevir The serum concentration of Dihydrotestosterone can be increased when it is combined with Voxilaprevir. Approved Warfarin Dihydrotestosterone may increase the anticoagulant activities of Warfarin. Approved Zimelidine The serum concentration of Dihydrotestosterone can be increased when it is combined with Zimelidine. Withdrawn - Food Interactions
- Not Available
References
- Synthesis Reference
A. Glenn Braswell, Aftab J. Ahmed, "Composition for inhibiting production of dihydrotestosterone to treat benign prostate hyperplasia." U.S. Patent US6264996, issued October, 1996.
US6264996- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB02961
- KEGG Drug
- D07456
- KEGG Compound
- C03917
- ChemSpider
- 10189
- BindingDB
- 18161
- ChEBI
- 16330
- ChEMBL
- CHEMBL27769
- HET
- DHT
- Wikipedia
- Dihydrotestosterone
- ATC Codes
- A14AA01 — Androstanolone
- A14AA — Androstan derivatives
- A14A — ANABOLIC STEROIDS
- A14 — ANABOLIC AGENTS FOR SYSTEMIC USE
- A — ALIMENTARY TRACT AND METABOLISM
- PDB Entries
- 1d2s / 1dht / 1f5f / 1i37 / 1i38 / 1kdk / 1kdm / 1t5z / 1t63 / 1t65 … show 34 more
- MSDS
- Download (111 KB)
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 181 °C PhysProp water solubility 525 mg/mL (at 25 °C) YALKOWSKY,SH & DANNENFELSER,RM (1992) logP 3.55 HANSCH,C ET AL. (1995) - Predicted Properties
Property Value Source Water Solubility 0.00998 mg/mL ALOGPS logP 3.37 ALOGPS logP 3.41 ChemAxon logS -4.5 ALOGPS pKa (Strongest Acidic) 19.38 ChemAxon pKa (Strongest Basic) -0.88 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 2 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 37.3 Å2 ChemAxon Rotatable Bond Count 0 ChemAxon Refractivity 83.6 m3·mol-1 ChemAxon Polarizability 34.69 Å3 ChemAxon Number of Rings 4 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule Yes ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 1.0 Blood Brain Barrier + 0.9818 Caco-2 permeable + 0.8846 P-glycoprotein substrate Substrate 0.57 P-glycoprotein inhibitor I Non-inhibitor 0.5631 P-glycoprotein inhibitor II Non-inhibitor 0.846 Renal organic cation transporter Non-inhibitor 0.7884 CYP450 2C9 substrate Non-substrate 0.7715 CYP450 2D6 substrate Non-substrate 0.93 CYP450 3A4 substrate Substrate 0.7314 CYP450 1A2 substrate Non-inhibitor 0.6853 CYP450 2C9 inhibitor Non-inhibitor 0.9071 CYP450 2D6 inhibitor Non-inhibitor 0.971 CYP450 2C19 inhibitor Non-inhibitor 0.9025 CYP450 3A4 inhibitor Non-inhibitor 0.8546 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9647 Ames test Non AMES toxic 0.9414 Carcinogenicity Non-carcinogens 0.9182 Biodegradation Not ready biodegradable 0.9686 Rat acute toxicity 1.9757 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9444 hERG inhibition (predictor II) Non-inhibitor 0.576
Spectra
- Mass Spec (NIST)
- Download (11.2 KB)
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available GC-MS Spectrum - EI-B GC-MS splash10-015c-8970000000-ef0c6a4fd9c52be30284 GC-MS Spectrum - EI-B GC-MS splash10-001l-1790000000-60cff73adc796876d469 Mass Spectrum (Electron Ionization) MS splash10-000x-9870000000-f6d80b2a53942c9af50b Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available 13C NMR Spectrum 1D NMR Not Applicable
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as androgens and derivatives. These are 3-hydroxylated C19 steroid hormones. They are known to favor the development of masculine characteristics. They also show profound effects on scalp and body hair in humans.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Steroids and steroid derivatives
- Sub Class
- Androstane steroids
- Direct Parent
- Androgens and derivatives
- Alternative Parents
- 3-oxo-5-alpha-steroids / 17-hydroxysteroids / Secondary alcohols / Cyclic ketones / Cyclic alcohols and derivatives / Organic oxides / Hydrocarbon derivatives
- Substituents
- Androgen-skeleton / 3-oxosteroid / 3-oxo-5-alpha-steroid / 17-hydroxysteroid / Oxosteroid / Hydroxysteroid / Cyclic alcohol / Cyclic ketone / Secondary alcohol / Ketone
- Molecular Framework
- Aliphatic homopolycyclic compounds
- External Descriptors
- 3-oxo steroid, 17beta-hydroxy steroid, 17beta-hydroxyandrostan-3-one (CHEBI:16330) / C19 steroids (androgens) and derivatives, Androstane and derivatives, Androgens (C03917) / C19 steroids (androgens) and derivatives (LMST02020042)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Zinc ion binding
- Specific Function
- Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Transcription ...
- Gene Name
- AR
- Uniprot ID
- P10275
- Uniprot Name
- Androgen receptor
- Molecular Weight
- 98987.9 Da
References
- Askew EB, Gampe RT Jr, Stanley TB, Faggart JL, Wilson EM: Modulation of androgen receptor activation function 2 by testosterone and dihydrotestosterone. J Biol Chem. 2007 Aug 31;282(35):25801-16. Epub 2007 Jun 25. [PubMed:17591767]
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Testosterone dehydrogenase (nad+) activity
- Specific Function
- Favors the reduction of estrogens and androgens. Also has 20-alpha-HSD activity. Uses preferentially NADH.
- Gene Name
- HSD17B1
- Uniprot ID
- P14061
- Uniprot Name
- Estradiol 17-beta-dehydrogenase 1
- Molecular Weight
- 34949.715 Da
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Zinc ion binding
- Specific Function
- Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissu...
- Gene Name
- ESR1
- Uniprot ID
- P03372
- Uniprot Name
- Estrogen receptor
- Molecular Weight
- 66215.45 Da
References
- Kojima H, Iida M, Katsura E, Kanetoshi A, Hori Y, Kobayashi K: Effects of a diphenyl ether-type herbicide, chlornitrofen, and its amino derivative on androgen and estrogen receptor activities. Environ Health Perspect. 2003 Apr;111(4):497-502. [PubMed:12676605]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Zinc ion binding
- Specific Function
- Receptor for both mineralocorticoids (MC) such as aldosterone and glucocorticoids (GC) such as corticosterone or cortisol. Binds to mineralocorticoid response elements (MRE) and transactivates targ...
- Gene Name
- NR3C2
- Uniprot ID
- P08235
- Uniprot Name
- Mineralocorticoid receptor
- Molecular Weight
- 107066.575 Da
References
- Takeda AN, Pinon GM, Bens M, Fagart J, Rafestin-Oblin ME, Vandewalle A: The synthetic androgen methyltrienolone (r1881) acts as a potent antagonist of the mineralocorticoid receptor. Mol Pharmacol. 2007 Feb;71(2):473-82. Epub 2006 Nov 14. [PubMed:17105867]
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, nad(p)h as one donor, and incorporation of one atom of oxygen
- Specific Function
- Catalyzes the side-chain cleavage reaction of cholesterol to pregnenolone.
- Gene Name
- CYP11A1
- Uniprot ID
- P05108
- Uniprot Name
- Cholesterol side-chain cleavage enzyme, mitochondrial
- Molecular Weight
- 60101.87 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Steroid 17-alpha-monooxygenase activity
- Specific Function
- Conversion of pregnenolone and progesterone to their 17-alpha-hydroxylated products and subsequently to dehydroepiandrosterone (DHEA) and androstenedione. Catalyzes both the 17-alpha-hydroxylation ...
- Gene Name
- CYP17A1
- Uniprot ID
- P05093
- Uniprot Name
- Steroid 17-alpha-hydroxylase/17,20 lyase
- Molecular Weight
- 57369.995 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Oxygen binding
- Specific Function
- Catalyzes the formation of aromatic C18 estrogens from C19 androgens.
- Gene Name
- CYP19A1
- Uniprot ID
- P11511
- Uniprot Name
- Aromatase
- Molecular Weight
- 57882.48 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Carriers
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Androgen binding
- Specific Function
- Functions as an androgen transport protein, but may also be involved in receptor mediated processes. Each dimer binds one molecule of steroid. Specific for 5-alpha-dihydrotestosterone, testosterone...
- Gene Name
- SHBG
- Uniprot ID
- P04278
- Uniprot Name
- Sex hormone-binding globulin
- Molecular Weight
- 43778.755 Da
References
- Metzger J, Schnitzbauer A, Meyer M, Soder M, Cuilleron CY, Hauptmann H, Huber E, Luppa PB: Binding analysis of 1alpha- and 17alpha-dihydrotestosterone derivatives to homodimeric sex hormone-binding globulin. Biochemistry. 2003 Nov 25;42(46):13735-45. [PubMed:14622020]
- Hauptmann H, Metzger J, Schnitzbauer A, Cuilleron CY, Mappus E, Luppa PB: Syntheses and ligand-binding studies of 1 alpha- and 17 alpha-aminoalkyl dihydrotestosterone derivatives to human sex hormone-binding globulin. Steroids. 2003 Sep;68(7-8):629-39. [PubMed:12957668]
Transporters
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Xenobiotic-transporting atpase activity
- Specific Function
- Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
- Gene Name
- ABCB1
- Uniprot ID
- P08183
- Uniprot Name
- Multidrug resistance protein 1
- Molecular Weight
- 141477.255 Da
References
- Fedoruk MN, Gimenez-Bonafe P, Guns ES, Mayer LD, Nelson CC: P-glycoprotein increases the efflux of the androgen dihydrotestosterone and reduces androgen responsive gene activity in prostate tumor cells. Prostate. 2004 Apr 1;59(1):77-90. [PubMed:14991868]
Drug created on June 13, 2005 07:24 / Updated on October 02, 2017 05:16